Dynavax Technologies reported $3.11M in Interest Expense on Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Adma Biologics ADMA:US $ 3.25M 0.05M
Agenus AGEN:US $ 16.68M 0.79M
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
Amgen AMGN:US $ 281M 4M
Biogen BIIB:US $ 56.4M 8.3M
Biomarin Pharmaceutical BMRN:US $ 3.82M 0.01M
Bristol Myers Squibb BMY:US $ 330M 23M
Dynavax Technologies DVAX:US $ 3.11M 1.6M
Gilead Sciences GILD:US $ 256M 1M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 13.09M 0.21M
Neurocrine Biosciences NBIX:US $ 6.2M 0.2M
Novartis NOVN:VX 201M 1000K
Pfizer PFE:US $ 316M 20M
Regeneron Pharmaceuticals REGN:US $ 14.4M 0.2M
Sarepta Therapeutics SRPT:US $ 15.83M 0.18M
Tg Therapeutics TGTX:US $ 1.62M 0.28M
Vertex Pharmaceuticals VRTX:US $ 15.48M 0.2M